Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Functional Molecules in Tracing and Cancer Therapeutics

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 5624

Share This Special Issue

Special Issue Editor

Prof. Dr. Kang-Nan Wang

E-Mail Website
Guest Editor

State Key Laboratory of Crystal Materials, Shandong University, Jinan 250100, China
Interests: sensing and imaging; photodynamic diagnostic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Increasing applications of functional targeting molecules in cells and organisms have been reported in recent years. These molecules are designed as sensing, imaging, anti-inflammation, and antineoplastic agents. Among them, some insightful researchers even integrate multiple functionalities in one molecule. Researchers continuously explore novel functional molecules for disease therapeutics, including targeted drug delivery systems, imaging agents for tumor/inflammation characterization, and molecular probes for detecting specific biomarkers associated with cancer and other diseases. By harnessing the unique properties of these functional molecules, such as their ability to emit fluorescence or generate a signal in response to specific conditions, researchers gain valuable insights into the intricate workings of cells and tissues as diagnosis probes. By selectively targeting cancer cells, these materials act as drugs that deliver a lethal dose of reactive oxygen species, leading to localized cell death and tumor destruction. In conclusion, the development of functional molecules for sensing, imaging, tracing, and cancer therapeutics has transformed the landscape of medical research and diagnostics. Manuscripts may cover a range of topics, including but not limited to the following:

Preparing and screening functional molecules of various applications.
Amplifying functional molecules with an affinity for the target substances, including but not limited to proteins and nucleic acid.
Drug delivery systems, including targeted molecules or targeted subcellular localization.
Potential cancer or inflammation-related biomarkers discovery and their pharmaceutical evaluation.

Prof. Dr. Kang-Nan Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

functional molecules
fluorescence imaging
targeted therapy of cancer
pharmaceutical evaluation

Published Papers (6 papers)

Download All Papers

Research

Jump to: Review

17 pages, 4780 KiB

Open AccessArticle

Synthesis, Characterization, Cytotoxicity, Cellular Imaging, Molecular Docking, and ADMET Studies of Piperazine-Linked 1,8-Naphthalimide-Arylsulfonyl Derivatives

by Ashanul Haque, Khalaf M. Alenezi, Ahmed Al-Otaibi, Abdulmohsen Khalaf Dhahi Alsukaibi, Ataur Rahman, Ming-Fa Hsieh, Mei-Wen Tseng and Wai-Yeung Wong

Int. J. Mol. Sci. 2024, 25(2), 1069; https://doi.org/10.3390/ijms25021069 - 15 Jan 2024

Cited by 1 | Viewed by 906

Abstract

To reduce the mortality and morbidity associated with cancer, new cancer theranostics are in high demand and are an emerging area of research. To achieve this goal, we report the synthesis and characterization of piperazine-linked 1,8-naphthalimide-arylsulfonyl derivatives (SA1–SA7). These compounds were synthesized in good yields following a two-step protocol and characterized using multiple analytical techniques. In vitro cytotoxicity and fluorescent cellular imaging of the compounds were assessed against non-cancerous fibroblast (3T3) and breast cancer (4T1) cell lines. Although the former study indicated the safe nature of the compounds (viability = 82–95% at 1 μg/mL), imaging studies revealed that the designed probes had good membrane permeability and could disperse in the whole cell cytoplasm. In silico studies, including molecular docking, molecular dynamics (MD) simulation, and ADME/Tox results, indicated that the compounds had the ability to target CAIX-expressing cancers. These findings suggest that piperazine-linked 1,8-naphthalimide-arylsulfonyl derivatives are potential candidates for cancer theranostics and a valuable backbone for future research. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures

Figure 1

17 pages, 3667 KiB

Open AccessArticle

POSS Engineering of Multifunctional Nanoplatforms for Chemo-Mild Photothermal Synergistic Therapy

by Zhengye Gu, Xiaochuan Geng, Shanyi Guang and Hongyao Xu

Int. J. Mol. Sci. 2024, 25(2), 1012; https://doi.org/10.3390/ijms25021012 - 13 Jan 2024

Viewed by 743

Abstract

Chemo-mild photothermal synergistic therapy can effectively inhibit tumor growth under mild hyperthermia, minimizing damage to nearby healthy tissues and skin while ensuring therapeutic efficacy. In this paper, we develop a multifunctional study based on polyhedral oligomeric sesquisiloxane (POSS) that exhibits a synergistic therapeutic effect through mild photothermal and chemotherapy treatments (POSS-SQ-DOX). The nanoplatform utilizes SQ-N as a photothermal agent (PTA) for mild photothermal, while doxorubicin (DOX) serves as the chemotherapeutic drug for chemotherapy. By incorporating POSS into the nanoplatform, we successfully prevent the aggregation of SQ-N in aqueous solutions, thus maintaining its excellent photothermal properties both in vitro and in vivo. Furthermore, the introduction of polyethylene glycol (PEG) significantly enhances cell permeability, which contributes to the remarkable therapeutic effect of POSS-SQ-DOX NPs. Our studies on the photothermal properties of POSS-SQ-DOX NPs demonstrate their high photothermal conversion efficiency (62.3%) and stability, confirming their suitability for use in mild photothermal therapy. A combination index value (CI = 0.72) verified the presence of a synergistic effect between these two treatments, indicating that POSS-SQ-DOX NPs exhibited significantly higher cell mortality (74.7%) and tumor inhibition rate (72.7%) compared to single chemotherapy and mild photothermal therapy. This observation highlights the synergistic therapeutic potential of POSS-SQ-DOX NPs. Furthermore, in vitro and in vivo toxicity tests suggest that the absence of cytotoxicity and excellent biocompatibility of POSS-SQ-DOX NPs provide a guarantee for clinical applications. Therefore, utilizing near-infrared light-triggering POSS-SQ-DOX NPs can serve as chemo-mild photothermal PTA, while functionalized POSS-SQ-DOX NPs hold great promise as a novel nanoplatform that may drive significant advancements in the field of chemo-mild photothermal therapy. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures

Figure 1

18 pages, 12448 KiB

Open AccessArticle

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2

by Pengming Pan, Yichao He, Tongtong Geng, Zhongtang Li, Zhongjun Li and Xiangbao Meng

Int. J. Mol. Sci. 2023, 24(22), 16290; https://doi.org/10.3390/ijms242216290 - 14 Nov 2023

Viewed by 1056

Abstract

Inhibition of the extracellular signal-regulated kinases 1/2 (ERK1/2) alone or in combination with other targets has emerged as a promising treatment strategy for a variety of human tumors. In addition to the development of inhibitors, the development of ERK1/2 degraders is an alternative approach to decrease its activity. We synthesized proteolysis-targeting chimeras (PROTACs) as effective ERK1/2 degraders, among which B1-10J showed high degradative activity, with DC₅₀ of 102 nM and cytotoxic IC₅₀ of 2.2 μM against HCT116 cells. Moreover, B1-10J dose-dependently inhibited tumor cell migration. Xenograft experiments in nude mice demonstrated that B1-10J inhibited HCT116 tumor cell growth and achieved significant regression of tumors at a daily dose of 25 mg/kg. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures

Graphical abstract

29 pages, 8444 KiB

Open AccessArticle

Activation of Chaperone-Mediated Autophagy Inhibits the Aryl Hydrocarbon Receptor Function by Degrading This Receptor in Human Lung Epithelial Carcinoma A549 Cells

by Rui Xiong, Dan Shao, Sandra Do and William K. Chan

Int. J. Mol. Sci. 2023, 24(20), 15116; https://doi.org/10.3390/ijms242015116 - 12 Oct 2023

Viewed by 1121

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor and a substrate protein of a Cullin 4B E3 ligase complex responsible for diverse cellular processes. In the lung, this receptor is responsible for the bioactivation of benzo[a]pyrene during tumorigenesis. Realizing that the AHR function is affected by its expression level, we are interested in the degradation mechanism of AHR in the lung. Here, we have investigated the mechanism responsible for AHR degradation using human lung epithelial A549 cells. We have observed that the AHR protein levels increase in the presence of chloroquine (CQ), an autophagy inhibitor, in a dose-dependent manner. Treatment with 6-aminonicotinamide (6-AN), a chaperone-mediated autophagy (CMA) activator, decreases AHR protein levels in a concentration-dependent and time-dependent manner. This decrease suppresses the ligand-dependent activation of the AHR target gene transcription, and can be reversed by CQ but not MG132. Knockdown of lysosome-associated membrane protein 2 (LAMP2), but not autophagy-related 5 (ATG5), suppresses the chloroquine-mediated increase in the AHR protein. AHR is resistant to CMA when its CMA motif is mutated. Suppression of the epithelial-to-mesenchymal transition in A549 cells is observed when the AHR gene is knocked out or the AHR protein level is reduced by 6-AN. Collectively, we have provided evidence supporting that AHR is continuously undergoing CMA and activation of CMA suppresses the AHR function in A549 cells. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures

Figure 1

20 pages, 10553 KiB

Open AccessArticle

Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells

by Johanna Loris, Lena Hanesch, Gerd Bauerschmitz, Julia Gallwas and Carsten Gründker

Int. J. Mol. Sci. 2023, 24(18), 13705; https://doi.org/10.3390/ijms241813705 - 05 Sep 2023

Viewed by 863

Abstract

Whether G protein-coupled estrogen receptor 1 (GPER1) is tumor-promoting or tumor-suppressive depends in part on tumor entity. Little is known about the function of GPER1 in vulvar carcinoma. In this work, we aim to clarify what role GPER1 plays in vulvar cancer, tumor-promoting or tumor-suppressive. Localization of GPER1 in A431 and CAL-39 vulvar carcinoma cells was examined by immunofluorescence. Using a tissue microarray of vulvar neoplasias, the correlation between GPER1 expression and grade of malignancy was investigated. A431 and CAL-39 cells were treated either with GPER1 agonist G1 or antagonist G36. Proliferation was quantified by BrdU assay and viability examined using Resazurin assay. Morphological changes were analyzed by microscopy and measured using ImageJ. Cell migration was analyzed by gap closure assay. Clonogenic potential was tested by colony and sphere formation. Expression of estrogen receptors was examined by Western blot. GPER1 was found consistently expressed in vulvar neoplasia tissues. The immune-reactive score was found to be significantly higher in tissue samples of lymph node metastases and neoplasias with grade 3. In A431 and CAL-39 vulvar carcinoma cells, GPER1 expression was mainly found in the cytoplasm and nuclei. Treatment of A431 and CAL-39 cells with GPER1 agonist G1 resulted in a decrease in proliferation and migration. In addition, colony formation and tumor sphere formation were reduced. Furthermore, morphological signs of necrosis and reduction in cell viability after G1 treatment were observed. The GPER1 antagonist G36 did not have significant effects on vulvar carcinoma cells. Neither agonist G1 nor antagonist G36 treatment resulted in altered expression of estrogen receptors. Activation of GPER1 with GPER1 agonist G1 reduces the tumorigenic potential of the vulvar carcinoma cells. It can be deduced from this that GPER1 appears to have a tumor-suppressive effect in vulvar carcinoma. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures

Figure 1

Review

Jump to: Research

29 pages, 2026 KiB

Open AccessReview

Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer

by Yun Ju Lee, Woo Ryung Kim, Eun Gyung Park, Du Hyeong Lee, Jung-min Kim, Hae Jin Shin, Hyeon-su Jeong, Hyun-Young Roh and Heui-Soo Kim

Int. J. Mol. Sci. 2024, 25(8), 4548; https://doi.org/10.3390/ijms25084548 - 21 Apr 2024

Viewed by 572

Abstract

Colorectal cancer (CRC) is the third most prevalent cancer to be diagnosed, and it has a substantial mortality rate. Despite numerous studies being conducted on CRC, it remains a significant health concern. The disease-free survival rates notably decrease as CRC progresses, emphasizing the urgency for effective diagnostic and therapeutic approaches. CRC development is caused by environmental factors, which mostly lead to the disruption of signaling pathways. Among these pathways, the Wingless/Integrated (Wnt) signaling pathway, Phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway, Mitogen-Activated Protein Kinase (MAPK) signaling pathway, Transforming Growth Factor-β (TGF-β) signaling pathway, and p53 signaling pathway are considered to be important. These signaling pathways are also regulated by non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). They have emerged as crucial regulators of gene expression in CRC by changing their expression levels. The altered expression patterns of these ncRNAs have been implicated in CRC progression and development, suggesting their potential as diagnostic and therapeutic targets. This review provides an overview of the five key signaling pathways and regulation of ncRNAs involved in CRC pathogenesis that are studied to identify promising avenues for diagnosis and treatment strategies. Full article

(This article belongs to the Special Issue Functional Molecules in Tracing and Cancer Therapeutics)

► Show Figures